International Journal of Environmental Sciences
ISSN: 2229-7359
Vol. 11 No. 5s, 2025
https://www.theaspd.com/ijes.php

Fetal-Maternal Cell-Free DNA and RNA in Plasma: Biochemical Insights into Non-Invasive Prenatal Testing (NIPT)

Ian Pranandi[1*]

[1]Department of Biochemistry, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta 14440, Indonesia

[*]Corresponding Author:

Email ID: ian.pranandi@atmajaya.ac.id

Abstract

Non-Invasive Prenatal Testing (NIPT) has revolutionized prenatal care by enabling early detection of fetal genetic conditions through analysis of cell-free nucleic acids in maternal plasma. This review explores the biochemical properties, origins, and clinical significance of fetal-maternal cell-free DNA (cfDNA) and RNA (cfRNA), emphasizing their pivotal roles in the success and advancement of NIPT. We discuss the molecular characteristics, release and clearance mechanisms, and analytical approaches for detecting cfDNA and cfRNA, including quantitative PCR and next-generation sequencing. Furthermore, the review highlights current clinical applications, such as aneuploidy screening, fetal sex determination, and emerging roles in detecting monogenic disorders and maternal-fetal complications. Limitations of current technologies and potential confounders are also addressed. Finally, we explore future directions, including multi-omic integration and cfRNA-based biomarkers for real-time fetal health monitoring. Together, these insights reinforce the growing utility of cell-free nucleic acids as powerful tools for non-invasive, personalized prenatal diagnostics.

Keywords: *cell-free DNA, cell-free RNA, non-invasive prenatal testing, fetal fraction, plasma biomarkers*

INTRODUCTION

Prenatal screening and diagnosis are critical components of obstetric care, enabling early detection of fetal chromosomal abnormalities and other genetic disorders.[1] Traditionally, invasive procedures such as chorionic villus sampling (CVS) and amniocentesis have served as the gold standard for definitive prenatal diagnosis.[2,3] However, these methods carry a small but significant risk of miscarriage and other complications, prompting a demand for safer alternatives.[4]

The discovery of cell-free fetal DNA (cffDNA) in maternal plasma by Lo et al. in 1997 marked a turning point in prenatal medicine.[5] This finding laid the foundation for the development of Non-Invasive Prenatal Testing (NIPT), a revolutionary approach that allows for genetic analysis of the fetus using

maternal blood samples.[6] In addition to cffDNA, recent studies have identified the presence of fetal cell-free RNA (cfRNA) in maternal circulation, offering further insights into placental and fetal gene expression profiles.[7]

Cell-free nucleic acids (cfNAs), which include both DNA and RNA fragments, are released into maternal circulation primarily from placental trophoblasts through apoptosis and necrosis. These molecules carry specific biochemical signatures that distinguish them from maternal cfNAs, such as size, methylation patterns, and gene expression profiles.[8] Advances in molecular biology and sequencing technologies have enabled the accurate detection and quantification of cfDNA and cfRNA, making NIPT a highly sensitive and specific tool for early fetal screening.[7,9]

This review aims to provide a comprehensive biochemical overview of fetal-maternal cfDNA and cfRNA in maternal plasma and their roles in the development and refinement of NIPT. We will discuss their origins, molecular characteristics, and detection methods, and explore how these insights translate into current and future clinical applications. Understanding the biochemical landscape of cfNAs is essential for optimizing NIPT's diagnostic potential and expanding its applications in personalized prenatal care.[8,9]

II. Biochemical Nature of Cell-Free Fetal DNA and RNA

A. Origin and Release Mechanisms

Fetal cell-free DNA (cffDNA) and cell-free RNA (cfRNA) originate primarily from the placental trophoblasts, specifically the syncytiotrophoblast layer, which is in direct contact with maternal blood. The release of these nucleic acids into the maternal circulation occurs predominantly through programmed cell death (apoptosis) and, to a lesser extent, necrosis and active secretion via extracellular vesicles such as exosomes and microvesicles.[8,10]

Unlike maternal cfDNA, which can originate from multiple tissues, cffDNA is placental in origin and may not always reflect the true fetal genome, especially in cases of confined placental mosaicism.[11] In contrast, cfRNA offers dynamic insight into fetal and placental gene expression, allowing the assessment of developmental physiology and pathological states such as preeclampsia and fetal growth restriction.[9,10]

Table 1. Comparison of Maternal and Fetal Cell-Free Nucleic Acids[8]

Characteristic	Maternal cfDNA/cfRNA	Fetal cfDNA/cfRNA
Origin	Multiple somatic tissues	Syncytiotrophoblast (placenta)
Release mechanism	Apoptosis, necrosis, secretion	Mainly apoptosis of placental cells
Half-life	~15–30 minutes	~15–30 minutes
Fragment size	Broad (~166 bp typical)	Shorter fragments (~143–145 bp)
Methylation pattern	Tissue-specific	Unique hypomethylated regions

Expression dynamics (RNA)	Relatively stable gene expression	Dynamic, developmental stage-dependent

B. Molecular Characteristics

1. Size Distribution and Fragmentation

One of the key biochemical distinctions between maternal and fetal cfDNA is their fragment size. Fetal cfDNA fragments are typically shorter (~143–145 base pairs) than maternal cfDNA (~166 base pairs), likely due to differences in nucleosome spacing and degradation processes. This size difference allows for bioinformatic enrichment of fetal cfDNA during sequencing.[11,12]

Similarly, cfRNA molecules are often encapsulated in extracellular vesicles, bound to proteins (e.g., Argonaute 2), or exist in ribonucleoprotein complexes. These associations protect them from enzymatic degradation in plasma and influence their detectability and stability.[9,10]

2. Epigenetic Signatures

Fetal cfDNA is often hypomethylated compared to maternal DNA, especially in promoter regions. This difference is exploited in certain NIPT platforms to distinguish fetal-derived sequences from maternal background using methylation-specific sequencing or PCR techniques.[11,13]

3. Transcriptomic Profile of cfRNA

cfRNA detected in maternal plasma comprises various RNA classes, including mRNA, microRNA (miRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA). The cfRNA transcriptome reflects real-time placental and fetal gene expression and correlates with gestational age and physiological states.[9,10]

Notably, genes such as CGA, CGB, PLAC4, ERVW-1, and PAPPA are consistently detected in maternal plasma and have been proposed as biomarkers for placental function and pathology.[8]

Table 2. Molecular Properties of cfDNA and cfRNA in Maternal Plasma[9,11]

Parameter	cfDNA	cfRNA
Size	~143–166 bp (fetal shorter than maternal)	Variable; often <200 nt, some >1 kb
Stability	High (fragmented, but stable)	Lower (unless vesicle/protein-bound)
Biological function	Genetic blueprint	Reflects gene expression and regulation

Methylation analysis	Yes, for fetal-maternal discrimination	Limited, but possible in some contexts
Detection challenges	Low fetal fraction, maternal background	RNA instability, contamination, splicing
Diagnostic use	Aneuploidy, CNV, monogenic disorders	Gene expression, preeclampsia, GDM

C. Clearance and Half-Life

The clearance of cell-free fetal DNA (cffDNA) and RNA (cfRNA) from maternal circulation is a critical feature distinguishing them from other circulating biomarkers. Their short half-life, typically between 15 to 30 minutes, ensures that the levels of these nucleic acids provide a real-time reflection of fetal and placental status. This property is particularly valuable in clinical settings for monitoring acute changes in fetal condition or placental pathology.[8,13]

The primary pathways for clearance include:

- Hepatic and splenic uptake by the reticuloendothelial system.
- Renal excretion (especially for smaller nucleic acid fragments).
- Enzymatic degradation by circulating nucleases (e.g., DNase I and RNase A).
- Phagocytosis by macrophages in the liver and spleen.[10,11]

Interestingly, this rapid turnover explains why fetal cfDNA and cfRNA are typically undetectable within a few hours postpartum, which confirms their placental origin. This transient presence reduces the risk of long-term interference from past pregnancies but also underscores the importance of timely and standardized sample processing to avoid degradation and inaccurate measurements.[8,13]

Factors that can prolong clearance or affect turnover include:

- Increased maternal BMI, which can dilute fetal cfDNA concentrations.
- Renal or hepatic dysfunction, affecting clearance capacity.
- Placental abnormalities, which may alter the release and degradation dynamics.[8,14]

D. Temporal and Spatial Dynamics

The temporal profile of cfDNA and cfRNA varies significantly across the course of pregnancy. For cfDNA, the fetal fraction (i.e., the proportion of fetal-derived cfDNA relative to total cfDNA in maternal plasma) increases steadily with gestational age, reaching clinically useful levels by 9–10 weeks of gestation, and plateauing in the second trimester. This makes early first-trimester screening feasible, although it requires high-sensitivity techniques to detect low-abundance fetal DNA.[11,12]

Fetal cfRNA, on the other hand, shows a stage-specific expression pattern, reflecting the gene regulatory events occurring in the fetus and placenta. For example:

- First trimester: transcripts related to implantation and early placental development (e.g., *H19*, *HAND1*).
- Second trimester: genes involved in angiogenesis and immune tolerance (e.g., *FLT1*, *PP13*).
- Third trimester: genes implicated in labor readiness and metabolic adaptation (e.g., *CGB*, *CRH*).[9,10]

These dynamic changes in cfRNA offer an opportunity to use it as a temporal biomarker, not just for fetal genetic analysis but also for functional assessments like risk stratification for preeclampsia, preterm birth, or fetal growth restriction.[9]

Spatially, cfDNA freely circulates in maternal plasma, whereas cfRNA is predominantly packaged in extracellular vesicles (EVs), such as exosomes and microvesicles. These vesicles originate from the syncytiotrophoblast and provide protection from enzymatic degradation. Their lipid bilayer structure not only preserves cfRNA integrity but also enables targeted intercellular communication, suggesting a possible role in maternal physiological adaptation to pregnancy.[8,13]

Table 3. Temporal Trends in Cell-Free Fetal Nucleic Acids During Pregnancy[8,13]

Trimester	**cfDNA**	**cfRNA**
1st	Low fetal fraction (~4–6%)	Early placental genes (e.g., *H19*, *CGA*)
2nd	Increasing fetal fraction (~10–15%)	Angiogenesis, immune genes (*FLT1*, *PP13*)
3rd	Plateau or slightly increased	Labor and metabolic signals (*CRH*, *LEP*, *CGB*)

Technical and Biological Variability

Accurate analysis of fetal cfDNA and cfRNA is influenced by a combination of technical and biological variables that can significantly affect test sensitivity, specificity, and reproducibility.[8]

1. Biological Variables

- Maternal BMI: High body mass index is associated with increased maternal cfDNA, which dilutes fetal signals and reduces fetal fraction.
- Gestational age: Early gestational stages have lower fetal DNA levels; cfRNA expression is also stage-dependent.
- Multiple gestation: Twins or higher-order pregnancies complicate interpretation due to varying fetal contributions.
- Placental mosaicism: Confined placental mosaicism can cause false-positive or false-negative results in cfDNA-based tests.[7,11]

2. Technical Variables

- Sample collection: Blood should be collected in specialized cfDNA-stabilizing tubes to prevent leukocyte lysis and maternal DNA contamination.
- Centrifugation: Inadequate plasma separation leads to genomic DNA contamination.
- Storage and transport: Delays in processing or improper temperature control can degrade cfRNA and increase background noise.
- Extraction protocols: Different isolation kits vary in yield, purity, and efficiency for short nucleic acid fragments.
- Sequencing depth and bioinformatics: Deeper sequencing improves resolution but increases cost; computational pipelines must distinguish fetal vs maternal reads.[9,12]

To reduce variability and improve inter-laboratory consistency, international consortia (e.g., ISPD, ACOG) have published standardized protocols for preanalytical handling, extraction, and reporting of NIPT results.[1,6]

Table 4. Factors Influencing NIPT Performance Based on cfDNA/cfRNA Analysis[1,6]

Factor	Impact on NIPT	Mitigation Strategy
High maternal BMI	↓ Fetal fraction, reduced test sensitivity	Consider redraw or use alternative assays
Early gestational age	Low fetal cfDNA and unstable cfRNA	Delay testing until ≥10 weeks gestation
Improper sample handling	cfRNA degradation, cfDNA contamination	Use stabilizing tubes, rapid processing
Low sequencing depth	Reduced resolution for CNVs/monogenic disorders	Use high-depth targeted sequencing
Confined placental mosaicism	Discordance between placental and fetal genotype	Confirm positives with invasive testing

III. Methods for Detection and Analysis

The successful clinical implementation of non-invasive prenatal testing (NIPT) depends on highly sensitive and specific methodologies for the detection, isolation, and analysis of cell-free fetal DNA (cffDNA) and RNA (cfRNA) from maternal plasma. Due to the small quantity and fragmented nature of fetal nucleic acids, particularly during early gestation, standardized and optimized workflows are critical for accurate and reproducible results.[6]

A. Sample Collection and Preanalytical Handling

1. Blood Collection

The first step in any cfDNA or cfRNA-based test is proper blood collection. Venous blood is typically drawn into EDTA tubes or specialized cfDNA preservation tubes (e.g., Streck Cell-Free DNA BCT®). The latter contains stabilizers that prevent maternal white blood cell lysis, reducing background genomic DNA contamination.[6,13]

2. Plasma Separation

Blood samples must be processed promptly, within 6 hours for EDTA tubes or up to 72 hours for stabilizing tubes, to separate plasma from blood cells. This involves:

- First centrifugation (e.g., 1,600 × g for 10 min): removes cells.
- Second high-speed spin (e.g., 16,000 × g): removes cell debris and residual nucleated cells.

Failing to perform timely and proper centrifugation risks contamination with maternal genomic DNA, particularly problematic for low fetal fraction samples.[6,13]

3. Storage and RNA Handling

Plasma samples for cfRNA are more fragile and should be processed or stored at -80°C with RNase inhibitors if available. Since RNA is prone to degradation, extra precautions (e.g., use of RNase-free reagents, low temperatures, and rapid handling) are essential.[6,13]

B. Nucleic Acid Isolation

1. cfDNA Extraction

Various commercial kits are available for cfDNA extraction, commonly based on silica membrane or magnetic bead separation. Key features of optimized kits include:

- High recovery of short DNA fragments (~100–200 bp).
- Low elution volume to concentrate DNA.
- Minimal contamination with protein or salt.[11]

Automated platforms (e.g., QIAsymphony, MagNA Pure) have improved reproducibility and scalability in clinical settings.[11]

2. cfRNA Extraction

Isolation of cfRNA is more challenging due to its instability and lower abundance. Commonly used methods include:

- Phenol-chloroform-based extraction (e.g., TRIzol LS).
- Silica column-based kits for small RNA.
- Enrichment using exosome isolation or ribosomal RNA depletion to increase signal-to-noise ratio.[10]

RNA integrity is generally assessed using Bioanalyzer, and quantification is performed with Qubit RNA assays or RT-qPCR for reference transcripts (e.g., *ACTB, GAPDH*).[10]

C. Detection and Quantification Techniques

1. Quantitative PCR (qPCR) and Digital PCR (dPCR)

qPCR has been traditionally used for specific target detection such as Y-chromosome sequences (for fetal sex determination) or RHD gene (for RhD status). However, its limitations include lower resolution and difficulty in multiplexing.[16]

Digital PCR (dPCR) provides absolute quantification without the need for standard curves and is highly useful for detecting low-frequency variants, such as point mutations or mosaic aneuploidies.[17]

2. Next-Generation Sequencing (NGS)

NGS has become the gold standard for high-throughput cfDNA-based NIPT. Common approaches include:

- Massively parallel shotgun sequencing (MPSS): counts cfDNA reads across the genome to detect aneuploidy (e.g., Trisomy 21, 18, 13).
- Targeted sequencing panels: focus on selected genomic regions to reduce cost while retaining accuracy.
- Whole genome or exome sequencing: allows for broader mutation detection, including CNVs and single-gene disorders (though still primarily in research settings).[18,19]

For cfRNA, RNA-seq can provide transcriptome-wide profiling, but is currently more common in research due to technical and cost limitations.[19]

3. Bioinformatics and Fetal Fraction Estimation

A critical component of NIPT is distinguishing fetal-derived cfDNA from maternal background. Bioinformatic pipelines apply:

- Z-score analysis: for aneuploidy detection.
- Fetal fraction estimation using:
    - Y-chromosome reads (for male fetuses).
    - Methylation-based models.
    - Fragment size distribution.
    - SNP allele frequency analysis.[20,21]

These pipelines must be robust to handle low fetal fraction samples (<4%) and reduce false positives/negatives.[21]

D. Quality Control and Standardization

To ensure clinical validity, every step from sample collection to bioinformatic interpretation must be subjected to rigorous quality control, including:

- Use of internal controls (e.g., synthetic spike-ins).
- Thresholds for fetal fraction and read depth.
- External validation using reference materials or proficiency testing programs.[19,21]

Several professional organizations (e.g., ACMG, ISPD, CAP) have published guidelines for laboratory implementation of cfDNA-based NIPT, including analytical and clinical validation protocols.[6,22]

E. Summary Table

Table 5. Summary of Methods for cfDNA/cfRNA Analysis in NIPT[6,22]

Step	cfDNA Methods	cfRNA Methods
Sample collection	EDTA or cfDNA BCT tubes	EDTA + RNase inhibitors or specialized RNA-stabilizing tubes
Plasma separation	Double centrifugation within 6–72 hrs	Immediate processing or -80°C storage
Extraction	Magnetic bead/silica-based kits (short fragment optimized)	TRIzol LS, exosome isolation, RNA cleanup kits
Quantification	Qubit dsDNA HS, qPCR, dPCR	Qubit RNA HS, RT-qPCR
Detection platform	qPCR, dPCR, MPSS, targeted NGS	RT-qPCR, microarray, RNA-seq
Data analysis	Z-score, fetal fraction (Y-DNA, SNPs, methylation, size)	Expression profiling, clustering, pathway enrichment
Quality control	Internal controls, fetal fraction cutoff, external validation	RNA integrity check, spike-in controls

IV. Clinical Applications of cfDNA and cfRNA in Non-Invasive Prenatal Testing (NIPT)

Over the past decade, the clinical utility of cfDNA-based NIPT has expanded rapidly beyond basic aneuploidy screening. Recent advances in molecular analysis now allow for early, accurate, and non-invasive detection of a variety of fetal conditions, many of which previously required invasive procedures.[11,12] Additionally, cfRNA is emerging as a complementary biomarker with applications in functional fetal assessment, offering novel diagnostic insights into placental health and pregnancy complications.[9,10]

A. Detection of Common Aneuploidies

The most well-established application of cfDNA in NIPT is the detection of common fetal aneuploidies, especially:

- Trisomy 21 (Down syndrome).

- Trisomy 18 (Edwards syndrome).
- Trisomy 13 (Patau syndrome).[23]

Using massively parallel sequencing (MPSS) or targeted sequencing, cfDNA testing achieves >99% sensitivity and specificity for Trisomy 21, with slightly lower performance for Trisomies 18 and 13. The high negative predictive value makes NIPT particularly valuable as a first-line screening test, reducing the need for invasive follow-up testing in low-risk pregnancies.[23,24]

Clinical Notes:

- Recommended by ACOG and SMFM for all pregnant individuals regardless of risk category.
- False positives may still occur due to confined placental mosaicism or maternal chromosomal abnormalities.[1,24]

B. Sex Chromosome Aneuploidies

NIPT is capable of detecting abnormalities in the number of X and Y chromosomes, including:

- Monosomy X (Turner syndrome).
- Klinefelter syndrome (XXY).
- Triple X syndrome (XXX).
- XYY syndrome.[23]

While analytical detection is reliable, clinical interpretation is more complex due to variable expressivity and milder phenotypes, leading some experts to caution against routine screening for sex chromosome anomalies without appropriate pre-test counseling.[24,25]

C. Fetal Sex Determination

Fetal sex can be accurately determined as early as 7 weeks of gestation by detecting Y-chromosome–specific sequences (e.g., *SRY*, *DYS14*) in maternal plasma.[24]

Clinical applications:

- Early preparation in cases of X-linked disorders.
- Psychosocial and family planning considerations.
- Essential for RhD genotyping in alloimmunized pregnancies.[24]

D. RhD Genotyping in Alloimmunized Pregnancies

cfDNA-based testing can determine fetal RhD status non-invasively from maternal plasma. This helps:

- Avoid unnecessary anti-D prophylaxis in RhD-negative women carrying RhD-negative fetuses.
- Guide management of alloimmunized pregnancies to monitor risk of hemolytic disease of the fetus and newborn (HDFN).[23,26]

This test has near-perfect sensitivity and specificity when performed after 11 weeks of gestation.[26]

E. Detection of Subchromosomal Abnormalities and CNVs

Advanced NIPT platforms can identify copy number variations (CNVs) and microdeletions, such as:

- 22q11.2 deletion syndrome (DiGeorge syndrome).
- 1p36 deletion.
- Cri-du-chat syndrome (5p deletion).
- Prader-Willi/Angelman syndrome (15q11–13).[24,26]

However, these conditions are rarer and often associated with higher false positive rates, especially in low-risk populations. Current professional guidelines recommend offering these tests with caution and clear pre-test counseling due to uncertain predictive values.[24]

F. Single-Gene Disorders and Monogenic Disease Detection

Emerging NIPT applications now include targeted sequencing for specific single-gene disorders (SGDs), including:

- β-thalassemia and sickle cell disease.
- Cystic fibrosis.
- Achondroplasia.
- Noonan syndrome.
- Duchenne muscular dystrophy (via relative haplotype dosage analysis).[23]

Such tests require prior parental genotyping and advanced computational modeling but offer promise for carrier couples seeking early answers without invasive procedures.[23]

G. cfRNA as a Biomarker for Placental and Fetal Health

While not yet routine in clinical practice, cfRNA is an emerging biomarker in pregnancy physiology and pathology. Its dynamic expression reflects placental function and intrauterine conditions in real-time.[25]

Table 6. Potential Clinical Applications of cfRNA[25]

Condition	**Associated cfRNA Markers**	**Clinical Relevance**
Preeclampsia	*FLT1*, *ENG*, *LEP*	Early prediction weeks before onset
Fetal Growth Restriction	*PLAC4*, *PAPPA*, *IGF2*	Reflects placental insufficiency
Preterm Birth	*IL1B*, *CRH*, *STAT3*	Inflammatory transcript patterns may predict spontaneous PTB

Gestational Diabetes Mellitus	*ADIPOQ*, *LEP*, *TNF*	Transcriptomic shifts in metabolic regulation genes
Fetal sex and maturity	*XIST*, *CGA*, *CGB*, *ERVW-1*	Sex prediction, maturity assessment via hormone transcripts

As technology advances and analytical costs decrease, cfRNA testing may evolve into a non-invasive tool for real-time fetal monitoring, complementary to anatomical and biochemical assessments.[25]

H. Multimodal Testing and Future Directions

The integration of cfDNA and cfRNA data, possibly with proteomics, metabolomics, or AI-powered clinical decision tools, represents the next frontier of NIPT. Such multimodal platforms may eventually:

- Detect fetal developmental anomalies not limited to chromosomal defects.
- Monitor fetal organ maturation (e.g., lungs, brain).
- Identify maternal conditions affecting pregnancy outcome (e.g., preeclampsia, infection).[24,26]

In the future, pan-omic NIPT may transform prenatal care into a fully non-invasive, personalized precision health service.[24]

Conclusion of Section

cfDNA-based NIPT is now firmly established as a reliable screening tool for fetal aneuploidies and sex determination, with expanding roles in CNVs and monogenic disease detection. Meanwhile, cfRNA holds promise as a real-time transcriptomic biomarker reflecting placental and fetal physiology. Together, these technologies are reshaping the landscape of prenatal diagnostics, offering safer, earlier, and more comprehensive insights than ever before.[23,25]

V. Advantages and Limitations of cfDNA/cfRNA-Based NIPT

Non-invasive prenatal testing (NIPT) using cell-free fetal DNA (cffDNA) and RNA (cfRNA) has transformed prenatal screening by enabling early, accurate, and low-risk assessment of fetal genetic and physiological status.[6,15] Despite its many benefits, several technical, biological, and ethical limitations must be considered to interpret results appropriately and ensure safe clinical use. This section outlines the key advantages and limitations of cfDNA and cfRNA in NIPT.[8]

A. Advantages of cfDNA and cfRNA-Based NIPT

1. Non-Invasive and Safe

NIPT is performed using a simple maternal blood draw, avoiding the risks associated with invasive procedures such as amniocentesis and chorionic villus sampling (CVS), which carry a miscarriage risk of ~0.1–0.3%.[15]

2. Early Detection

Fetal cfDNA can be detected as early as 7–9 weeks of gestation, allowing for first-trimester screening. Early diagnosis enhances patient autonomy and broadens reproductive options.[13]

3. High Sensitivity and Specificity

- For Trisomy 21: >99% sensitivity and specificity.
- Low false-positive rates in singleton pregnancies.
- High negative predictive value, making it a reliable screening tool.[13,14]

4. Broadening Diagnostic Scope

- Detection of sex chromosome anomalies, CNVs, monogenic disorders.
- cfRNA expands NIPT into real-time physiological monitoring of the placenta and fetus.[8,15]

5. Dynamic Biomarkers

cfRNA reflects active gene expression, enabling functional insight into gestational diseases (e.g., preeclampsia, preterm birth), which is not possible through DNA-based screening alone.[13,14]

Table 7. Key Advantages of cfDNA and cfRNA-Based NIPT[8,13]

Advantage	**cfDNA**	**cfRNA**
Safety	Non-invasive (blood-based)	Non-invasive
Timing	Detectable from ~9 weeks	Increases through gestation
Sensitivity (Trisomy 21)	>99%	Still under study
Scope of detection	Aneuploidies, CNVs, monogenic diseases	Placental function, gene expression

Dynamic monitoring	Limited	Yes (temporal transcriptional profiling)

B. Limitations and Challenges

Despite its strengths, NIPT has limitations related to both technical constraints and biological variability, as well as broader clinical and ethical implications.[6,15]

1. Low Fetal Fraction

The fetal fraction—the proportion of cfDNA originating from the placenta—is critical for test accuracy. A low fetal fraction (<4%) may lead to:

- False-negative results.
- Test failure or need for redraw.[8,13]

Contributors to low fetal fraction include:

- Early gestation (<10 weeks).
- High maternal BMI.
- Aneuploidy (e.g., trisomy 13 or triploidy).
- Poor placental health.[8]

2. Confined Placental Mosaicism (CPM)

Because fetal cfDNA primarily originates from the placenta, CPM (when the placenta has a genetic abnormality not present in the fetus) may cause:

- False-positive or false-negative results.
- Discordance between NIPT and invasive diagnostic results.[14,15]

3. False Positives from Maternal Conditions

- Maternal chromosomal abnormalities (e.g., XXX, X0).
- Undiagnosed maternal malignancy.
- Vanishing twins.[8,23]

These can release abnormal cfDNA into the maternal circulation, leading to erroneous interpretations.[8]

4. Limited Scope for cfRNA Testing

- Still largely in research phase.

- Challenges include RNA instability, low abundance, and high background noise.
- Clinical utility not yet standardized or FDA-approved.[10]

5. Interpretation and Ethical Dilemmas

- Ambiguous findings (e.g., CNVs of uncertain significance).
- Incidental findings (e.g., maternal health issues).
- Patient anxiety and pressure for further testing or pregnancy termination.[6]

Table 8. Limitations and Potential Consequences in NIPT[6,8]

Limitation	**Cause**	**Impact on Clinical Outcome**
Low fetal fraction	High BMI, early gestation, placental pathology	Inconclusive or false-negative result
Confined placental mosaicism	Genetic discordance between fetus and placenta	False-positive or false-negative findings
Maternal genomic variation	Structural variants or sex chromosome anomalies	Misinterpretation of fetal condition
Vanishing twin or multiple gestation	Residual cfDNA from demised co-twin	False positives, complexity in interpretation
RNA degradation	Delayed processing, poor sample handling	Loss of cfRNA signal, reduced diagnostic reliability
Limited standardization for cfRNA	Lack of clinical guidelines	Restricted to research; not clinically actionable yet
Ethical concerns	Ambiguous results or incidental findings	Need for genetic counseling and careful communication

C. Clinical and Ethical Considerations

As NIPT becomes more comprehensive, pre-test and post-test counseling are essential. Patients must understand:

- The screening nature of NIPT (not diagnostic unless confirmed by invasive testing).
- Possible need for confirmatory tests (e.g., CVS, amniocentesis).
- The scope and limitations of the test being offered.
- The implications of unanticipated findings, particularly for CNVs and maternal incidental diagnoses.[6,15]

Professional guidelines from ACOG, ISPD, and NSGC recommend that NIPT be offered with informed consent, and that results be interpreted in the context of clinical, family, and ultrasonographic data.[1,6]

Conclusion of Section

NIPT via cfDNA and cfRNA has become an indispensable tool in modern prenatal care due to its safety, sensitivity, and expanding diagnostic scope. Nonetheless, its limitations, including low fetal fraction, placental mosaicism, and ethical complexities, necessitate cautious interpretation and appropriate genetic counseling. With continued refinement, integration of cfRNA, and bioinformatics innovation, the future of NIPT promises to be even more powerful and informative.[6,15]

VI. Future Perspectives and Research Directions

As non-invasive prenatal testing (NIPT) continues to evolve, both cfDNA and cfRNA analysis are poised to play even more central roles in prenatal care. Future developments aim not only to enhance the accuracy and diagnostic scope of these tests, but also to transform NIPT from a static genetic screen into a dynamic window into fetal and placental biology.[6,15] Below, we outline the key areas of growth and innovation that are shaping the next generation of NIPT technologies.

A. Expansion to Monogenic and Polygenic Disorders

Beyond aneuploidies and large chromosomal aberrations, NIPT is gradually being extended to detect single-gene disorders (SGDs) and even polygenic risk scores.[24]

Developments include:

- Relative haplotype dosage (RHDO) analysis for maternally inherited recessive disorders (e.g., β-thalassemia, cystic fibrosis).
- De novo mutation detection (e.g., achondroplasia, Noonan syndrome).
- Polygenic risk estimation (e.g., type 1 diabetes, autism spectrum disorder), though still controversial and ethically complex.[24,25]

As sequencing technology and bioinformatics improve, these approaches may offer non-invasive alternatives for genetic conditions traditionally diagnosed via invasive means.[24]

B. Integration of cfRNA for Functional Monitoring

While cfDNA gives static genetic information, cfRNA offers dynamic insight into gene expression, fetal development, and placental function in real time. Future NIPT platforms may incorporate cfRNA transcriptomics to:

- Predict pregnancy complications (e.g., preeclampsia, preterm birth).

- Monitor fetal maturity (e.g., lung development for timing of delivery).
- Track immune or metabolic adaptation of the fetus.
- Provide sex-specific transcriptomic data for personalized fetal medicine.[8,13]

Large longitudinal cohorts and machine learning-based analysis of cfRNA profiles may help identify robust biomarker panels for routine screening.[13]

C. Multi-Omics and Systems Biology Approaches

To gain a holistic view of fetal and placental biology, future NIPT may combine:

- Genomics (cfDNA for aneuploidy and monogenic diseases).
- Transcriptomics (cfRNA for placental health and fetal development).
- Epigenomics (methylation patterns to distinguish fetal from maternal DNA).
- Proteomics and metabolomics (non-nucleic acid biomarkers for functional assessment).[13,14]

These multi-omics strategies will allow for comprehensive, system-wide evaluation of pregnancy, enabling the transition from disease detection to health optimization.[13]

Potential applications:

- Identifying fetal stress and hypoxia.
- Monitoring maternal-fetal immune interactions.
- Early detection of placental insufficiency before clinical symptoms arise.[8,13]

D. Artificial Intelligence and Predictive Modeling

The complexity and volume of sequencing and transcriptomic data call for advanced analytical tools. AI and machine learning (ML) are being increasingly applied to:

- Improve fetal fraction estimation.
- Distinguish true-positive from false-positive calls.
- Develop predictive models for complications (e.g., early-onset preeclampsia).
- Integrate genomic and clinical data to personalize risk predictions.[23,25]

These approaches could dramatically improve diagnostic accuracy, reduce unnecessary follow-up testing, and support clinical decision-making.[23]

E. Earlier and Broader Screening

Technological improvements in sensitivity and amplification now make NIPT feasible as early as 6–7 weeks of gestation. Combined with improved fetal fraction detection, this opens doors for:

- First-trimester or preconception screening.
- Expanded use in twin and IVF pregnancies.
- Potential universal screening regardless of maternal age or risk factors.[6,15]

Additionally, whole genome sequencing (WGS) of fetal cfDNA may offer comprehensive genetic profiles prenatally, though this raises significant ethical and regulatory questions around scope, consent, and data interpretation.[18,19]

F. Personalized Prenatal Medicine and Global Access

Ultimately, the vision for the future of NIPT includes:

- Personalized prenatal management, based on each pregnancy's molecular signature.
- Non-invasive prenatal therapeutics monitoring (e.g., response to maternal medications or intrauterine therapies).
- Affordable access to NIPT worldwide, including in low-resource settings, via cost-effective targeted assays and point-of-care platforms.[6,15]

Efforts must also address health equity, as disparities in access to advanced prenatal testing remain significant between high-income and low-resource settings.[6]

CONCLUSION OF SECTION

The future of cfDNA and cfRNA-based NIPT lies in expanding its diagnostic reach, improving predictive power, and integrating functional biology with genetics. With the aid of AI, multi-omic technologies, and global health strategies, NIPT is evolving into a comprehensive, personalized, and ethically informed tool for prenatal care, capable not only of identifying disease, but also of enhancing maternal-fetal health throughout pregnancy.[6,15]

CONCLUSION

The advent of non-invasive prenatal testing (NIPT) using cell-free fetal DNA (cfDNA) has redefined prenatal care, offering a safe, accurate, and early screening tool for chromosomal abnormalities and select genetic disorders. Complemented by emerging data on cell-free RNA (cfRNA), this technology now provides not only genetic but also dynamic physiological insight into the developing fetus and placenta.[10,11]

From a biochemical standpoint, cfDNA and cfRNA are distinguished by their origin, size, stability, and clearance dynamics. These features underpin their utility in early pregnancy screening and real-time

monitoring. Advances in sequencing technologies, data analysis, and sample handling have significantly improved the analytical performance of NIPT, with high sensitivity and specificity for common aneuploidies, fetal sex, and RhD genotyping. Meanwhile, cfRNA-based analysis is opening new frontiers in the prediction of pregnancy complications and fetal maturity assessment.[8,13]

Despite its strengths, NIPT is not without limitations. Factors such as low fetal fraction, confined placental mosaicism, and maternal biological confounders can influence test accuracy. Moreover, expanding the scope of testing raises important ethical considerations regarding incidental findings, counseling, and equitable access.[6,15]

Looking forward, the integration of cfDNA and cfRNA with multi-omic and artificial intelligence driven platforms promises a future in which prenatal diagnostics become fully non-invasive, personalized, and predictive. Such innovations will support not only the early detection of fetal abnormalities but also the continuous monitoring of fetal well-being throughout gestation, transforming NIPT from a diagnostic tool into a comprehensive system for prenatal health surveillance.[6,15]

REFERENCES

[1] American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 162: Prenatal Diagnostic Testing for Genetic Disorders. Obstet Gynecol. 2016;127(5):e108-e122. doi:10.1097/AOG.0000000000001405.

[2] Bhatt RK. Chorionic Villus Sampling. J Fetal Med. 2017 Jun;4(2):79–84. doi:10.1007/s40556-017-0115-5.

[3] Dimri N, Baijal A. Amniocentesis. J Fetal Med. 2016;3(3):131–135. doi:10.1007/s40556-016-0084-0.

[4] Mujezinovic F, Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet Gynecol. 2007 Sep;110(3):687–94. doi:10.1097/01.AOG.0000278820.54029.e3.

[5] Lo YMD, Corbetta N, Chamberlain PF, et al. Presence of Fetal DNA in Maternal Plasma and Serum. Lancet. 1997;350(9076):485-487.doi:10.1016/S0140-6736(97)02174-0.

[6] Jayashankar SS, Nasaruddin ML, Hassan MF, Dasrilsyah RA, Shafiee MN, Ismail NAS, et al. Non-Invasive Prenatal Testing (NIPT): Reliability, Challenges, and Future Directions. Diagnostics (Basel). 2023 Aug 2;13(15):2570.doi:10.3390/diagnostics13152570.

[7] Rasmussen M, Reddy M, Nolan R, Camunas-Soler J, Khodursky A, Scheller NM, et al. RNA profiles reveal signatures of future health and disease in pregnancy. Nature. 2022 Jan 20;601(7893):422–7.doi:10.1038/s41586-021-04249-w.

[8] Pös O, Biró O, Szemes T, Nagy B. Circulating cell-free nucleic acids: characteristics and applications. Eur J Hum Genet. 2018 Jul;26(7):937–45.doi:10.1038/s41431-018-0132-4.

[9] Gray KJ, Hemberg M, Karumanchi SA. Cell-Free RNA Transcriptome and Prediction of Adverse Pregnancy Outcomes. Clin Chem. 2022 Nov 3;68(11):1358–60. doi:10.1093/clinchem/hvac109.

[10] Jin H, Zhang Y, Fan Z, Wang X, Rui C, Xing S, et al. Identification of novel cell-free RNAs in maternal plasma as preterm biomarkers in combination with placental RNA profiles. J Transl Med. 2023 Apr 12;21(1):256.doi:10.1186/s12967-023-04083-w.

[11] Mackie FL, Hemming K, Allen S, Morris RK, Kilby MD. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. BJOG. 2017 Jan;124(1):32–46.doi:10.1111/1471-0528.14050.

[12] Bianchi DW, Chiu RWK. Sequencing of circulating cell-free DNA during pregnancy. N Engl J Med. 2018 Aug 2;379(5):464–73.doi:10.1056/NEJMra1705345.

[13] Rahat B, Ali T, Sapehia D, Mahajan A, Kaur J. Circulating cell-free nucleic acids as epigenetic biomarkers in precision medicine. Front Genet. 2020 Aug 11;11:844.doi:10.3389/fgene.2020.00844.

[14] Morisi N, Virzì GM, Ferrarini M, Alfano G, Zanella M, Ronco C, et al. Exploring the role of cell-free nucleic acids and peritoneal dialysis: a narrative review. Genes (Basel). 2024 Apr 26;15(5):553. doi:10.3390/genes15050553.

[15] Allyse M, Minear MA, Berson E, Sridhar S, Rote M, Hung A, Chandrasekharan S. Non-invasive prenatal testing: a review of international implementation and challenges. Int J Womens Health. 2015;7:113–26. doi:10.2147/IJWH.S67124.

[16] Zhao Y, Chen F, Li Q, Wang L, Fan C. Isothermal amplification of nucleic acids. Chem Rev. 2015 Nov 25;115(22):12491–545. doi:10.1021/acs.chemrev.5b00428.

[17] Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz AJ, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011 Nov 15;83(22):8604–10. doi:10.1021/ac202028g.

[18] Hu T, Chitnis N, Monos D, Dinh A. Next-generation sequencing technologies: an overview. Hum Immunol. 2021 Nov;82(11):801–11. doi:10.1016/j.humimm.2021.02.012.

[19] Baranova EE, Sagaydak OV, Galaktionova AM, Kuznetsova ES, Kaplanova MT, Makarova MV, et al. Whole genome non-invasive prenatal testing in prenatal screening algorithm: clinical experience from 12,700 pregnancies. BMC Pregnancy Childbirth. 2022 Aug 9;22(1):633. doi:10.1186/s12884-022-04966-8.

[20] Sousa SA, Leitão JH, Martins RC, Sanches JM, Suri JS, Giorgetti A. Bioinformatics applications in life sciences and technologies. Biomed Res Int. 2016;2016:3603827. doi:10.1155/2016/3603827.

[21] Peng XL, Jiang P. Bioinformatics approaches for fetal DNA fraction estimation in noninvasive prenatal testing. Int J Mol Sci. 2017 Feb;18(2):453.\ doi:10.3390/ijms18020453.

[22] Dungan JS, Klugman S, Darilek S, Malinowski J, Akkari YMN, Monaghan KG, et al. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023 Feb;25(2):100336. doi:10.1016/j.gim.2022.11.004.

[23] Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2015 Mar;45(3):249–66. doi:10.1002/uog.14791.

[24] Benn P, Borrell A, Crossley J, Cuckle H, Dugoff L, Gross S, et al. Aneuploidy screening: a position statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn. 2011 Jun;31(6):519–22.N doi:10.1002/pd.2730.

[25] Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014 Feb 27;370(9):799–808. doi:10.1056/NEJMoa1311037.

[26] Gil MM, Akolekar R, Quezada MS, Bregant B, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: meta-analysis. Fetal Diagn Ther. 2014;35(3):156–73. doi:10.1159/000358326.